ABL Bio Inc. (KOSDAQ:298380)

ABL Bio Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-55,529	-2,647	3,209	-43,558
Depreciation & Amortization	2,410	2,590	2,325	2,158
Loss (Gain) From Sale of Assets	7.03	2.64	-48	5.83
Loss (Gain) From Sale of Investments	-391.27	-1,132	592.13	-6,666
Stock-Based Compensation	2,889	6,001	4,382	7,521
Provision & Write-off of Bad Debts	-	-	-	-682.58
Other Operating Activities	2,004	-203.88	1,352	-15.18
Change in Unearned Revenue	-25,976	-31,859	63,562	-3,160
Change in Other Net Operating Assets	5,184	-1,113	-3,242	3,792
Operating Cash Flow	-69,403	-28,362	72,132	-40,605
Capital Expenditures	-9,023	-5,740	-2,055	-1,244
Sale of Property, Plant & Equipment	12.78	7.46	74.51	12
Cash Acquisitions	-	-	-21,256	-
Sale (Purchase) of Intangibles	-34.75	-104.41	-330.07	-21.4
Investment in Securities	-38,152	35,941	-46,234	21,458
Other Investing Activities	22.43	-20.49	-196.46	17.62
Investing Cash Flow	-47,174	29,884	-71,250	20,221
Long-Term Debt Issued	-	44,831	-	-
Long-Term Debt Repaid	-1,278	-43,130	-1,091	-959.45
Net Debt Issued (Repaid)	-1,278	1,701	-1,091	-959.45
Issuance of Common Stock	145,857	1,717	5,753	1,256
Other Financing Activities	-7.39	-1,981	-11.67	-12.36
Financing Cash Flow	144,572	1,437	4,649	284.13
Foreign Exchange Rate Adjustments	229.74	-29.86	-1,984	1,030
Net Cash Flow	28,225	2,929	3,547	-19,070
Free Cash Flow	-78,426	-34,102	70,076	-41,850
Free Cash Flow Margin	-234.79%	-52.03%	104.12%	-784.87%
Free Cash Flow Per Share	-1633.14	-712.77	1473.23	-890.99
Cash Interest Paid	165.07	2,521	1,205	-
Cash Income Tax Paid	-1,346	1,621	-2.6	-75.7
Levered Free Cash Flow	-62,856	-37,710	63,171	-
Unlevered Free Cash Flow	-62,833	-36,365	64,000	-
Change in Net Working Capital	19,518	32,186	-62,291	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.